Lees Pharmaceutical Holdings Stock Beta
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Lees Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Lees Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lees Pink Sheet. The fundamental analysis module provides a way to measure Lees Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lees Pharmaceutical pink sheet.
Lees |
Lees Pharmaceutical Holdings Company Beta Analysis
Lees Pharmaceutical's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Lees Pharmaceutical Beta | 0.91 |
Most of Lees Pharmaceutical's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lees Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Lees Pharmaceutical Holdings has a Beta of 0.9086. This is 5.65% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The beta for all United States stocks is notably lower than that of the firm.
Lees Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lees Pharmaceutical's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lees Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lees Pharmaceutical by comparing valuation metrics of similar companies.Lees Pharmaceutical is currently under evaluation in beta category among its peers.
Lees Pharmaceutical returns are very sensitive to returns on the market. As the market goes up or down, Lees Pharmaceutical is expected to follow.
Lees Fundamentals
| Return On Equity | -0.0531 | |||
| Return On Asset | 0.0591 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (1.58) % | |||
| Current Valuation | 123.64 M | |||
| Shares Outstanding | 588.84 M | |||
| Shares Owned By Insiders | 63.62 % | |||
| Shares Owned By Institutions | 6.36 % | |||
| Price To Book | 0.0002 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 1.27 B | |||
| Gross Profit | 806.28 M | |||
| EBITDA | 1.98 B | |||
| Net Income | 1.99 B | |||
| Cash And Equivalents | 368.05 M | |||
| Cash Per Share | 0.62 X | |||
| Total Debt | 84.09 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | 3.64 X | |||
| Cash Flow From Operations | 210.68 M | |||
| Number Of Employees | 1.32 K | |||
| Beta | 0.91 | |||
| Market Capitalization | 275.66 B | |||
| Total Asset | 3.64 B | |||
| Annual Yield | 52.23 % | |||
| Net Asset | 3.64 B | |||
| Last Dividend Paid | 0.041 |
About Lees Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lees Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lees Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lees Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |